

Robert G Gish

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/625151/publications.pdf>

Version: 2024-02-01

318
papers

15,351
citations

14653

66
h-index

20358

116
g-index

328
all docs

328
docs citations

328
times ranked

14610
citing authors

#	ARTICLE	IF	CITATIONS
1	A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2006, 354, 1001-1010.	27.0	1,345
2	Primary biliary cirrhosis in monozygotic and dizygotic twins: Genetics, epigenetics, and environment. <i>Gastroenterology</i> , 2004, 127, 485-492.	1.3	447
3	American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy. <i>Gastroenterology</i> , 2015, 148, 221-244.e3.	1.3	432
4	A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. <i>Hepatology</i> , 2001, 33, 424-432.	7.3	389
5	RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	343
6	Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. <i>Hepatology</i> , 1998, 27, 213-222.	7.3	324
7	Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B. <i>Gastroenterology</i> , 2007, 133, 1437-1444.	1.3	324
8	Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation.. <i>Journal of Clinical Investigation</i> , 1991, 88, 270-281.	8.2	302
9	Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. <i>Hepatology</i> , 1999, 29, 1581-1586.	7.3	281
10	Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. <i>Hepatology</i> , 2006, 44, 915-924.	7.3	278
11	Immunoregulatory cytokines in chronic hepatitis C virus infection: Pre- and posttreatment with interferon alfa. <i>Hepatology</i> , 1996, 24, 6-9.	7.3	270
12	Phase III Randomized Controlled Trial Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma Treated With Nilotrexed or Doxorubicin. <i>Journal of Clinical Oncology</i> , 2007, 25, 3069-3075.	1.6	249
13	A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients. <i>Gastroenterology</i> , 2005, 129, 1198-1209.	1.3	247
14	Severe Hepatotoxicity Associated with Nevirapine Use in HIV-Infected Subjects. <i>Journal of Infectious Diseases</i> , 2005, 191, 825-829.	4.0	225
15	Hepatitis C virus triggers mitochondrial fission and attenuates apoptosis to promote viral persistence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 6413-6418.	7.1	224
16	Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil 1 Gilead Sciences gratefully acknowledges the patients, investigators, and study site personnel who participated in clinical trials GS-98-437 and GS-98-438.. <i>Gastroenterology</i> , 2003, 125, 107-116.	1.3	221
17	Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities. <i>Antiviral Research</i> , 2015, 121, 47-58.	4.1	216
18	Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. <i>Gastroenterology</i> , 2003, 124, 925-932.	1.3	202

#	ARTICLE	IF	CITATIONS
19	Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners study. <i>Hepatology</i> , 2013, 57, 881-889.	7.3	195
20	A model to predict severe HCV-related disease following liver transplantation. <i>Hepatology</i> , 2003, 38, 34-41.	7.3	190
21	Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. <i>Hepatology</i> , 2007, 46, 324-329.	7.3	177
22	Model for end-stage liver disease (MELD) exception guidelines: Results and recommendations from the MELD exception study group and conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. <i>Liver Transplantation</i> , 2006, 12, S128-S136.	2.4	167
23	Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. <i>American Journal of Gastroenterology</i> , 2003, 98, 2060-2063.	0.4	165
24	Keratin 8 Mutations in Patients with Cryptogenic Liver Disease. <i>New England Journal of Medicine</i> , 2001, 344, 1580-1587.	27.0	163
25	Is chronic hepatitis B being undertreated in the United States?. <i>Journal of Viral Hepatitis</i> , 2011, 18, 377-383.	2.0	153
26	A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	7.3	139
27	Epidemiological and sequence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A. <i>Journal of General Virology</i> , 2004, 85, 811-820.	2.9	135
28	Hepatitis C virus as a systemic disease: reaching beyond the liver. <i>Hepatology International</i> , 2016, 10, 415-423.	4.2	131
29	Selection of chronic hepatitis B therapy with high barrier to resistance. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 341-353.	9.1	127
30	Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B*. <i>Journal of Viral Hepatitis</i> , 2010, 17, 16-22.	2.0	125
31	Changing nomenclature for PBC: From "cirrhosis"™ to "cholangitis"™. <i>Hepatology</i> , 2015, 62, 1620-1622.	7.3	125
32	Survival After Liver Transplantation in Patients With Hepatic Iron Overload: The National Hemochromatosis Transplant Registry. <i>Gastroenterology</i> , 2005, 129, 494-503.	1.3	121
33	The Impact of Chronic Hepatitis B on Quality of Life: A Multinational Study of Utilities from Infected and Uninfected Persons. <i>Value in Health</i> , 2008, 11, 527-538.	0.3	118
34	Elevated Alpha-Fetoprotein. <i>Clinics in Liver Disease</i> , 2015, 19, 309-323.	2.1	118
35	Characteristics of Hepatitis B Virus Isolates of Genotype G and Their Phylogenetic Differences from the Other Six Genotypes (A through F). <i>Journal of Virology</i> , 2002, 76, 6131-6137.	3.4	116
36	Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. <i>Antiviral Research</i> , 2015, 121, 97-108.	4.1	116

#	ARTICLE	IF	CITATIONS
37	Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. <i>Hepatology</i> , 2002, 35, 922-929.	7.3	114
38	Chronic hepatitis B: What should be the goal for new therapies?. <i>Antiviral Research</i> , 2013, 98, 27-34.	4.1	112
39	Fetal microchimerism alone does not contribute to the induction of primary biliary cirrhosis. <i>Hepatology</i> , 1999, 30, 833-838.	7.3	111
40	Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon- β 1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. <i>Hepatology</i> , 2007, 45, 569-578.	7.3	108
41	Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: A two-year study. <i>Journal of Hepatology</i> , 2005, 43, 60-66.	3.7	100
42	Changing Nomenclature for PBC: From "Cirrhosis" to "Cholangitis". <i>Gastroenterology</i> , 2015, 149, 1627-1629.	1.3	96
43	Coinfection with hepatitis B and D: Epidemiology, prevalence and disease in patients in Northern California. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1521-1525.	2.8	95
44	Hepatitis Delta: Epidemiology, Diagnosis and Management 36 Years After Discovery. <i>Current Gastroenterology Reports</i> , 2014, 16, 365.	2.5	94
45	Prevalence of Chronic Hepatitis B Virus Infection in the United States. <i>American Journal of Gastroenterology</i> , 2020, 115, 1429-1438.	0.4	92
46	A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. <i>Hepatology</i> , 2002, 36, 1253-1258.	7.3	91
47	Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. <i>Journal of Hepatology</i> , 2019, 70, 1008-1015.	3.7	90
48	Treating HCV with ribavirin analogues and ribavirin-like molecules. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 8-13.	3.0	88
49	Long-term follow-up of patients diagnosed with alcohol dependence or alcohol abuse who were evaluated for liver transplantation. <i>Liver Transplantation</i> , 2001, 7, 581-587.	2.4	86
50	Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome. <i>Liver Transplantation</i> , 2006, 12, S105-S107.	2.4	86
51	Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States. <i>Cancer</i> , 2016, 122, 2512-2523.	4.1	86
52	Changing nomenclature for PBC: From "cirrhosis" to "cholangitis". <i>Journal of Hepatology</i> , 2015, 63, 1285-1287.	3.7	85
53	Are infectious agents involved in primary biliary cirrhosis? A PCR approach. <i>Journal of Hepatology</i> , 1999, 31, 664-671.	3.7	84
54	RNA Interference Therapy With ARCA520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. <i>Hepatology</i> , 2020, 72, 19-31.	7.3	84

#	ARTICLE	IF	CITATIONS
55	MINIMAL CRITERIA FOR PLACEMENT OF ADULTS ON THE LIVER TRANSPLANT WAITING LIST. <i>Transplantation</i> , 1998, 66, 956-962.	1.0	84
56	Model for end-stage liver disease (MELD) exception for cholangiocarcinoma or biliary dysplasia. <i>Liver Transplantation</i> , 2006, 12, S95-S97.	2.4	82
57	Mycophenolate Mofetil in Autoimmune Hepatitis Patients Not Responsive or Intolerant to Standard Immunosuppressive Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 799-802.	4.4	82
58	Similar Risk of Renal Events Among Patients Treated With Tenofovir or Entecavir for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 941-946.	4.4	81
59	Rate of natural disease progression in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2003, 38, 307-314.	3.7	80
60	Survival After Liver Transplantation in Patients With Hepatic Iron Overload: The National Hemochromatosis Transplant Registry. <i>Gastroenterology</i> , 2005, 129, 494-503.	1.3	78
61	Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. <i>Liver International</i> , 2007, 27, 1394-1401.	3.9	78
62	Determination of hepatitis B virus genotype G by polymerase chain reaction with hemi-nested primers. <i>Journal of Virological Methods</i> , 2001, 98, 153-159.	2.1	76
63	Model for end-stage liver disease (MELD) exception for portopulmonary hypertension. <i>Liver Transplantation</i> , 2006, 12, S114-S116.	2.4	76
64	T1653 Mutation in the Box a Increases the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Genotype C Infection. <i>Clinical Infectious Diseases</i> , 2006, 42, 1-7.	5.8	73
65	Chronic Hepatitis B: Current Testing Strategies. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 666-676.	4.4	70
66	A research agenda for curing chronic hepatitis B virus infection. <i>Hepatology</i> , 2018, 67, 1127-1131.	7.3	70
67	Safety, Tolerability, and Pharmacokinetics of ARCA520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 350-362.	1.6	69
68	Global HBV burden: guesstimates and facts. <i>Hepatology International</i> , 2018, 12, 315-329.	4.2	68
69	Characterization of Hepatitis G Virus (GB-C Virus) Particles: Evidence for a Nucleocapsid and Expression of Sequences Upstream of the E1 Protein. <i>Journal of Virology</i> , 1998, 72, 2738-2744.	3.4	68
70	Development of Hepatocellular Carcinoma in Autoimmune Hepatitis Patients: A Case Series. <i>Digestive Diseases and Sciences</i> , 2011, 56, 578-585.	2.3	66
71	Eight genotypes (A-H) of hepatitis B virus infecting patients from San Francisco and their demographic, clinical, and virological characteristics. <i>Journal of Medical Virology</i> , 2004, 73, 516-521.	5.0	64
72	An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign-Born Persons Living in the United States. <i>Hepatology</i> , 2021, 74, 607-626.	7.3	64

#	ARTICLE	IF	CITATIONS
73	Model for end-stage liver disease (MELD) exception guidelines. <i>Liver Transplantation</i> , 2006, 12, S85-S87.	2.4	63
74	The Impact of Race/Ethnicity on the Clinical Epidemiology of Autoimmune Hepatitis. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 155-161.	2.2	61
75	Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 743-753.	8.1	60
76	Hepatocellular Carcinoma: Overcoming Challenges in Disease Management. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 252-261.	4.4	57
77	Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 173-185.	3.0	57
78	Optimization for the detection of hepatitis C virus antigens in the liver. <i>Journal of Hepatology</i> , 1994, 20, 143-147.	3.7	56
79	Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. <i>Journal of Medical Virology</i> , 2006, 78, 1296-1303.	5.0	56
80	Chronic Hepatitis B Infection. <i>Clinics in Liver Disease</i> , 2012, 16, 347-369.	2.1	54
81	Model for end-stage liver disease (MELD) exception for polycystic liver disease. <i>Liver Transplantation</i> , 2006, 12, S110-S111.	2.4	52
82	Targeted systemic therapies for hepatocellular carcinoma: Clinical perspectives, challenges and implications. <i>World Journal of Gastroenterology</i> , 2012, 18, 498.	3.3	52
83	A Pilot Study of Extended Duration Peginterferon Alfa-2a for Patients With Hepatitis B e Antigen-Negative Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2007, 102, 2718-2723.	0.4	50
84	Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. <i>Cancer Biomarkers</i> , 2012, 11, 161-171.	1.7	49
85	Long-term follow-up after liver transplantation in patients with hepatic iron overload. <i>Liver Transplantation</i> , 1999, 5, 369-374.	1.8	47
86	Virological response and safety outcomes in therapy-naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: A randomized, phase 2 study. <i>Journal of Hepatology</i> , 2007, 47, 51-59.	3.7	47
87	Alcoholic Liver Disease. <i>Clinics in Liver Disease</i> , 2016, 20, 563-580.	2.1	47
88	Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation. <i>Liver Transplantation</i> , 2014, 20, n/a-n/a.	2.4	46
89	Management of hepatitis C virus infection in the Asia-Pacific region: an update. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 52-62.	8.1	45
90	Frequent coinfection with hepatitis B virus strains of distinct genotypes detected by hybridization with type-specific probes immobilized on a solid-phase support. <i>Journal of Virological Methods</i> , 2003, 110, 29-35.	2.1	44

#	ARTICLE	IF	CITATIONS
91	PS-052-End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection. <i>Journal of Hepatology</i> , 2019, 70, e32.	3.7	44
92	Chronic Hepatitis B: A Critical Appraisal of Current Approaches to Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 233-248.	4.4	43
93	Safety and efficacy of viremagine versus ribavirin in ViSER2: Randomized, double-blind study in therapy-naïve hepatitis C patients. <i>Journal of Hepatology</i> , 2010, 52, 32-38.	3.7	43
94	Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B. <i>Pharmacoeconomics</i> , 2007, 25, 963-977.	3.3	42
95	The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: Notes from a recent workshop. <i>Cancer Biomarkers</i> , 2008, 4, 19-33.	1.7	41
96	Immunosuppression in Patients with Chronic Hepatitis B. <i>Current Hepatology Reports</i> , 2014, 13, 235-244.	0.9	41
97	Portal Vein Thrombosis. <i>Clinics in Liver Disease</i> , 2015, 19, 199-221.	2.1	41
98	A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma. <i>Hepatology Communications</i> , 2022, 6, 1753-1763.	4.3	41
99	Novel Changes in Glycosylation of Serum Apo-J in Patients with Hepatocellular Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1222-1229.	2.5	36
100	Changing nomenclature for PBC: From "cirrhosis"™ to "cholangitis"™. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, e57-e59.	1.5	36
101	Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States. <i>Hepatology</i> , 2015, 62, 1339-1341.	7.3	33
102	Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression. <i>Journal of Hepatology</i> , 1995, 22, 257-262.	3.7	32
103	One-step real-time PCR assay for detection and quantitation of hepatitis D virus RNA. <i>Journal of Virological Methods</i> , 2013, 193, 531-535.	2.1	32
104	Management of hepatitis C virus in special populations: Patient and treatment considerations. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 311-318.	4.4	31
105	Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 1240-1252.	3.7	31
106	The impact of pretransplant hepatic encephalopathy on survival following liver transplantation. <i>Liver Transplantation</i> , 2015, 21, 873-880.	2.4	31
107	Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 707-716.	3.1	31
108	AUTOIMMUNE LIVER DISEASE. <i>Clinics in Liver Disease</i> , 2001, 5, 287-314.	2.1	30

#	ARTICLE	IF	CITATIONS
109	De Novo Non-Alcoholic Fatty Liver Disease Following Orthotopic Liver Transplantation. <i>American Journal of Transplantation</i> , 2003, 3, 1413-1417.	4.7	30
110	Changing Nomenclature for PBC: From "Cirrhosis" to "Cholangitis". <i>American Journal of Gastroenterology</i> , 2015, 110, 1536-1538.	0.4	30
111	A simple and inexpensive point-of-care test for hepatitis B surface antigen detection: serological and molecular evaluation. <i>Journal of Viral Hepatitis</i> , 2014, 21, 905-908.	2.0	29
112	Drugs in Development for Hepatitis B. <i>Drugs</i> , 2017, 77, 1263-1280.	10.9	29
113	Classifying genotype F of hepatitis B virus into F1 and F2 subtypes. <i>World Journal of Gastroenterology</i> , 2005, 11, 6295.	3.3	29
114	The NS5A Replication Complex Inhibitors: Difference Makers?. <i>Clinics in Liver Disease</i> , 2011, 15, 627-639.	2.1	28
115	Liver disease in Viet Nam: Screening, surveillance, management and education: A 5-year plan and call to action. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 238-247.	2.8	28
116	Predictors of hepatic decompensation after TACE for hepatocellular carcinoma. <i>BMJ Open Gastroenterology</i> , 2015, 2, e000032.	2.7	28
117	Changing nomenclature for PBC: from "cirrhosis" to "cholangitis". <i>Gut</i> , 2015, 64, 1671-1672.	12.1	28
118	Future Therapies for Hepatitis C. <i>Antiviral Therapy</i> , 2006, 11, 397-408.	1.0	28
119	Successful Domino Liver Transplantation from a Patient with Methylmalonic Acidemia. <i>JIMD Reports</i> , 2015, 25, 87-94.	1.5	27
120	Changing incidence of reported viral hepatitis in China from 2004 to 2016: an observational study. <i>BMJ Open</i> , 2019, 9, e028248.	1.9	27
121	PS-080-Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold. <i>Journal of Hepatology</i> , 2019, 70, e51-e52.	3.7	27
122	Clinical Trial Results of New Therapies for HBV: Implications for Treatment Guidelines. <i>Seminars in Liver Disease</i> , 2005, 25, 29-39.	3.6	26
123	Hepatocellular Carcinoma Surveillance: A National Survey of Current Practices in the USA. <i>Digestive Diseases and Sciences</i> , 2014, 59, 3073-3077.	2.3	25
124	Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. <i>World Journal of Gastroenterology</i> , 2015, 21, 4644-4651.	3.3	25
125	Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. <i>Gut</i> , 2022, 71, 789-797.	12.1	25
126	Current Treatment and Future Directions in the Management of Chronic Hepatitis B Viral Infection. <i>Clinics in Liver Disease</i> , 2005, 9, 541-565.	2.1	24

#	ARTICLE	IF	CITATIONS
127	Model for end-stage liver disease (MELD) exception for bacterial cholangitis. <i>Liver Transplantation</i> , 2006, 12, S91-S92.	2.4	24
128	The Effector Domain of MARCKS Is a Nuclear Localization Signal that Regulates Cellular PIP2 Levels and Nuclear PIP2 Localization. <i>PLoS ONE</i> , 2015, 10, e0140870.	2.5	24
129	RNA Interference and Its Potential Applications to Chronic HBV Treatment: Results of a Phase I Safety and Tolerability Study. <i>Antiviral Therapy</i> , 2011, 16, 547-554.	1.0	23
130	Cellular mechanics of germ band retraction in <i>Drosophila</i> . <i>Developmental Biology</i> , 2013, 384, 205-213.	2.0	23
131	Differential Reductions in Viral Antigens Expressed from CCCDNA Integrated DNA in Treatment Na ⁺ ve HBEAG Positive and Negative Patients with Chronic HBV after RNA Interference Therapy with ARC-520. <i>Journal of Hepatology</i> , 2016, 64, S390-S391.	3.7	23
132	Global Perspective on Hepatitis B Virus Infections in the Era of Effective Vaccines. <i>Clinics in Liver Disease</i> , 2019, 23, 383-399.	2.1	23
133	Improving outcomes for patients with chronic hepatitis B. <i>Current Gastroenterology Reports</i> , 2007, 9, 14-22.	2.5	22
134	A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. <i>Hepatology International</i> , 2009, 3, 480-489.	4.2	22
135	Future Therapy for Hepatitis B Virus: Role of Immunomodulators. <i>Current Hepatology Reports</i> , 2016, 15, 237-244.	0.9	22
136	Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma. <i>Liver Transplantation</i> , 2016, 22, 1356-1366.	2.4	22
137	Views of US Voters on Compensating Living Kidney Donors. <i>JAMA Surgery</i> , 2016, 151, 710.	4.3	21
138	Birth cohort-specific disparities in hepatocellular carcinoma stage at diagnosis, treatment, and long-term survival. <i>Journal of Hepatology</i> , 2016, 64, 326-332.	3.7	21
139	Sodium benzoate for treatment of hepatic encephalopathy. <i>Gastroenterology and Hepatology</i> , 2013, 9, 219-27.	0.1	21
140	Elevated Expression of Tyrosine Kinase DDR2 in Primary Biliary Cirrhosis. <i>Autoimmunity</i> , 2002, 35, 521-529.	2.6	20
141	Inhibition of Hec1 as a novel approach for treatment of primary liver cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 511-520.	2.3	20
142	Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 1089-1097.	2.0	20
143	Hepatitis B in liver transplant recipients. <i>Liver Transplantation</i> , 2006, 12, S54-S64.	2.4	19
144	Hepatitis B in the Greater San Francisco Bay Area: an integrated programme to respond to a diverse local epidemic. <i>Journal of Viral Hepatitis</i> , 2011, 18, e40-51.	2.0	19

#	ARTICLE	IF	CITATIONS
145	Significance of hepatic expression of hepatitis C viral antigens in chronic hepatitis C. <i>Digestive Diseases and Sciences</i> , 1995, 40, 2595-2601.	2.3	18
146	Model for end-stage liver disease (MELD) exception for hereditary hemorrhagic telangiectasia. <i>Liver Transplantation</i> , 2006, 12, S108-S109.	2.4	18
147	Editorial: To "Be" or Not to "Be": That Is the Question. <i>American Journal of Gastroenterology</i> , 2009, 104, 1948-1952.	0.4	18
148	Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2009, 16, 784-789.	2.0	18
149	Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive, nucleoside-naïve patients treated with entecavir. <i>Antiviral Therapy</i> , 2013, 18, 691-698.	1.0	18
150	Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBS antigen. <i>Journal of Hepatology</i> , 2017, 66, S27.	3.7	18
151	Model for end-stage liver disease (MELD) exception for hepatic encephalopathy. <i>Liver Transplantation</i> , 2006, 12, S102-S104.	2.4	17
152	Chronic HBV infection outside treatment guidelines: is treatment needed?. <i>Antiviral Therapy</i> , 2012, 18, 229-235.	1.0	17
153	Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis. <i>PLoS ONE</i> , 2019, 14, e0220612.	2.5	17
154	Hepatocellular Carcinoma: Molecular and Genomic Guideline for the Clinician. <i>Clinics in Liver Disease</i> , 2011, 15, 307-321.	2.1	16
155	A Clinical Assessment of Wilson Disease in Patients With Concurrent Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 267-273.	2.2	16
156	Changing Nomenclature for PBC: From "Cirrhosis" to "Cholangitis". <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1867-1869.	4.4	16
157	Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States. <i>Journal of Viral Hepatitis</i> , 2019, 26, 350-361.	2.0	16
158	A review of liver transplantation for the dentist and guidelines for dental management. <i>Special Care in Dentistry</i> , 1993, 13, 74-80.	0.8	15
159	Genotyping and Genomic Sequencing in Clinical Practice. <i>Clinics in Liver Disease</i> , 2007, 11, 761-795.	2.1	15
160	Changing nomenclature for PBC: From "cirrhosis" to "cholangitis". <i>Digestive and Liver Disease</i> , 2015, 47, 924-926.	0.9	15
161	Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States. <i>Journal of Viral Hepatitis</i> , 2017, 24, 17-21.	2.0	15
162	Hepatitis B treatment: Current best practices, avoiding resistance. <i>Cleveland Clinic Journal of Medicine</i> , 2009, 76, S14-S19.	1.3	15

#	ARTICLE	IF	CITATIONS
163	The <sc>NAFLD–</sc>MAFLD</sc> debate: Is there a Consensus–Consensus methodology?. Liver International, 2022, 42, 742-748.	3.9	15
164	Ascending Multiple–Dose Pharmacokinetics of Virodine, a Prodrug of Ribavirin, in Adult Subjects With Compensated Hepatitis C Infection. Journal of Clinical Pharmacology, 2005, 45, 275-285.	2.0	14
165	<sc>U</sc>nited <sc>N</sc>etwork for <sc>O</sc>rgan <sc>S</sc>haring regional variations in appeal denial rates with non–standard Model for End–Stage Liver Disease/Pediatric End–Stage Liver Disease exceptions: support for a national review board. Clinical Transplantation, 2015, 29, 513-522.	1.6	14
166	Hepatitis B Core Antibody: Role in Clinical Practice in 2020. Current Hepatology Reports, 2020, 19, 254-265.	0.9	14
167	Model for end-stage liver disease (MELD) exception for cystic fibrosis. Liver Transplantation, 2006, 12, S98-S99.	2.4	13
168	Clinical outcomes of liver transplantation for HBV–related hepatocellular carcinoma: data from the NIH HBV OLT study. Clinical Transplantation, 2011, 25, E152-62.	1.6	13
169	Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease. Therapeutic Advances in Gastroenterology, 2016, 9, 887-897.	3.2	13
170	Identification of hepatitis C virus 2k/1b intergenotypic recombinants in Georgia. Liver International, 2018, 38, 451-457.	3.9	13
171	Metabolic Manifestations and Complications Associated With Chronic Hepatitis C Virus Infection. Gastroenterology and Hepatology, 2016, 12, 293-9.	0.1	13
172	Model for end-stage liver disease (MELD) exception for Budd-Chiari syndrome. Liver Transplantation, 2006, 12, S93-S94.	2.4	12
173	Do we need to MEND the MELD?. Liver Transplantation, 2007, 13, 486-487.	2.4	11
174	Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C. Liver International, 2007, 27, 1111-1118.	3.9	11
175	Current Treatment Guidelines for Chronic Hepatitis B and Their Applications. Journal of Clinical Gastroenterology, 2014, 48, 773-783.	2.2	11
176	Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment. Hepatology International, 2016, 10, 624-631.	4.2	11
177	Treatment of Chronically HBV-Infected Chimpanzees with RNA Interference Therapeutic ARC-520 LED to Potent Reduction of Viral MRNA, DNA and Proteins without Observed Drug Resistance. Journal of Hepatology, 2016, 64, S398.	3.7	11
178	Markov modeling in hepatitis B screening and linkage to care. Theoretical Biology and Medical Modelling, 2017, 14, 11.	2.1	11
179	Diagnostics of Hepatitis B Virus: Standard of Care and Investigational. Clinical Liver Disease, 2018, 12, 5-11.	2.1	11
180	Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel. BMJ Open Gastroenterology, 2019, 6, e000256.	2.7	11

#	ARTICLE	IF	CITATIONS
181	MAFLD and Cardiovascular Events: What Does the Evidence Show?. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2025-2028.	4.4	11
182	Treating hepatitis C: the state of the art. <i>Gastroenterology Clinics of North America</i> , 2004, 33, 1-9.	2.2	10
183	More Severe Deficits in Performance Status at Time of Liver Transplant is Associated With Significantly Higher Risk of Death Following Liver Transplantation. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, e392-e399.	2.2	10
184	Model for end-stage liver disease (MELD) exception for ascites. <i>Liver Transplantation</i> , 2006, 12, S88-S90.	2.4	9
185	Model for end-stage liver disease (MELD) exception for primary hyperoxaluria. <i>Liver Transplantation</i> , 2006, 12, S117-S118.	2.4	9
186	Society of interventional radiology critique and commentary on the cochrane report on transarterial chemoembolization. <i>Hepatology</i> , 2013, 57, 1675-1676.	7.3	9
187	Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules. <i>Translational Cancer Research</i> , 2013, 2, 460-471.	1.0	9
188	Acute liver failure in adults: an evidence-based management protocol for clinicians. <i>Gastroenterology and Hepatology</i> , 2012, 8, 161-212.	0.1	9
189	Hepatocellular carcinoma (HCC): current and evolving therapies. <i>IDrugs: the Investigational Drugs Journal</i> , 2008, 11, 198-203.	0.7	9
190	Transmission of hepatitis B virus through allotransplantation. <i>Liver Transplantation</i> , 1996, 2, 161-164.	1.8	8
191	Future Directions in the Treatment of Patients with Chronic Hepatitis C Virus Infection. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 1999, 13, 57-62.	1.7	8
192	Model for end-stage liver disease (MELD) exception for portal hypertensive gastrointestinal bleeding. <i>Liver Transplantation</i> , 2006, 12, S112-S113.	2.4	8
193	Customizing the Management of Chronic Hepatitis B Virus Infection. <i>Seminars in Liver Disease</i> , 2007, 27, 009-017.	3.6	8
194	Duplication of MER115 on chromosome 4 in patients with primary biliary cirrhosis. <i>Liver International</i> , 2009, 29, 375-383.	3.9	8
195	High rate of core promoter and precore mutations in patients with chronic hepatitis B. <i>Hepatology International</i> , 2015, 9, 209-217.	4.2	8
196	Epidemiology and Prevention of Tuberculosis and Chronic Hepatitis B Virus Infection in the United States. <i>Journal of Immigrant and Minority Health</i> , 2021, 23, 1267-1279.	1.6	8
197	GB Virus C (GBV-C/HGV) and E2 Antibodies in Children Pre-liver and Post-liver Transplant. <i>Pediatric Research</i> , 1999, 45, 795-798.	2.3	8
198	Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 374-382.	1.4	8

#	ARTICLE	IF	CITATIONS
199	A multidisciplinary approach to the management of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2010, 6, 1-16.	0.1	8
200	Treatment of chronic hepatitis B: New antiviral therapies. <i>Current Gastroenterology Reports</i> , 1999, 1, 20-26.	2.5	7
201	Model for end-stage liver disease (MELD) exception for uncommon hepatic tumors. <i>Liver Transplantation</i> , 2006, 12, S122-S123.	2.4	7
202	Model for end-stage liver disease (MELD) exception for unusual metabolic liver diseases. <i>Liver Transplantation</i> , 2006, 12, S124-S127.	2.4	7
203	Model for end-stage liver disease (MELD) exception small-for-size syndrome. <i>Liver Transplantation</i> , 2006, 12, S120-S121.	2.4	7
204	Hepatocellular Carcinoma: Locoregional and Targeted Therapies. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 599-610.	2.2	7
205	Chronic hepatitis B virus in the Philippines. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 945-952.	2.8	7
206	A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population. <i>Journal of Hepatology</i> , 2017, 66, S265.	3.7	7
207	Epidemiology and Natural History of Chronic Hepatitis B Virus Infection. , 2018, , 63-89.		7
208	Normal alkaline phosphatase levels are dependent on race/ethnicity: NationalGEP Health and Nutrition Examination Survey data. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000502.	2.7	7
209	Global trends and the impact of chronic hepatitis B and C on <scp>disabilityâ€adjusted</scp> life years. <i>Liver International</i> , 2022, 42, 2145-2153.	3.9	7
210	Model for end-stage liver disease (MELD) exception for severe pruritus. <i>Liver Transplantation</i> , 2006, 12, S119-S119.	2.4	6
211	Recent developments in the treatment of chronic hepatitis B virus infection. <i>Expert Opinion on Investigational Drugs</i> , 1995, 4, 95-115.	4.1	5
212	Characterization of anti-hepatitis C virus-positive sera not genotyped by restriction fragment length polymorphism or serology. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 14, 339-344.	2.8	5
213	Model for end-stage liver disease (MELD) exception for familial amyloidotic polyneuropathy. <i>Liver Transplantation</i> , 2006, 12, S100-S101.	2.4	5
214	Improving outcomes for patients with chronic hepatitis B. <i>Hepatology Research</i> , 2007, 37, S67-S78.	3.4	5
215	1007 RISK OF RENAL TOXICITY WITH TENOFOVIR DF (TDF) FOR CHRONIC HEPATITIS B (CHB). <i>Journal of Hepatology</i> , 2010, 52, S388-S389.	3.7	5
216	Clinical Management and Case Reports for the Treatment of Hepatocellular Carcinoma With Sorafenib. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 733-737.	2.2	5

#	ARTICLE	IF	CITATIONS
217	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. Clinics in Liver Disease, 2019, 23, 487-492.	2.1	5
218	Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. Gastroenterology and Hepatology, 2013, 9, 1-24.	0.1	5
219	Is there a serological difference between men and women with primary biliary cirrhosis?. American Journal of Gastroenterology, 1999, 94, 2482-2486.	0.4	4
220	Letter to the editors. Liver Transplantation, 2005, 11, 366-366.	2.4	4
221	Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment. AIDS Research and Therapy, 2011, 8, 29.	1.7	4
222	Medical interventions associated with HBV reactivation: Common and less common. Clinical Liver Disease, 2015, 5, 32-34.	2.1	4
223	Sofosbuvir/Ledipasvir without Ribavirin in the Treatment of Asians with Chronic Hepatitis C Virus Genotype 6 in the United States: Community-Based Real World Outcomes. Journal of Hepatology, 2016, 64, S815-S816.	3.7	4
224	Predicting HBsAg Clearance Responses during ARC-520 RNA Interference (RNAi) Therapy Based on HBsAg Epitope Profile Analysis. Journal of Hepatology, 2016, 64, S602.	3.7	4
225	Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?. Expert Review of Anti-Infective Therapy, 2016, 14, 41-56.	4.4	4
226	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. Clinics in Liver Disease, 2019, 23, 493-509.	2.1	4
227	Hepatitis C Vaccination: Where We Are and Where We Need to Be. Pathogens, 2021, 10, 1619.	2.8	4
228	Calcium compartmentation and exchange rates in primary hepatocyte culture. Analytical Biochemistry, 1990, 187, 187-196.	2.4	3
229	759 IMPACT OF ENTECAVIR VERSUS LAMIVUDINE ON HEPATIC COVALENTLY CLOSED-CIRCULAR DNA AND TOTAL HEPATIC HBVDNA IN NUCLEOSIDE-NAÏVE HBeAg POSITIVE CHRONIC HEPATITIS B PATIENTS. Journal of Hepatology, 2013, 58, S308-S309.	3.7	3
230	Clinical characteristics of antimitochondrial antibody-positive patients at a safety net health care system in Arizona. BMJ Open Gastroenterology, 2017, 4, e000158.	2.7	3
231	Assessment of treatment options for patients with hepatitis C virus recombinant form 2k/1b. Hepatology Research, 2021, 51, 156-165.	3.4	3
232	Low Prevalence of Vaccination or Documented Immunity to Hepatitis A and Hepatitis B Viruses Among Individuals with Chronic Liver Disease. American Journal of Medicine, 2021, 134, 882-892.	1.5	3
233	[563] PREDICTIVE VALUE FOR LOW LEVEL HEPATIC FIBROSIS IN CHRONIC HEPATITIS C (CMC) PATIENTS: COMPARISON OF FIVE NON-INVASIVE INDICES. Journal of Hepatology, 2007, 46, S214.	3.7	2
234	Diagnosis of Chronic Hepatitis B and the Implications of Viral Variants and Mutations. American Journal of Medicine, 2008, 121, i-OBC.	1.5	2

#	ARTICLE	IF	CITATIONS
235	Comparable efficacy with entecavir monotherapy and tenofovir+entecavir combination in chronic hepatitis B patients. <i>BMJ Open Gastroenterology</i> , 2015, 2, e000030.	2.7	2
236	Primary Care Physicians Utilizing the Echo Model Equally Effective as Subspecialists Treating HCV using Direct-Acting Antivirals-Only Regimens: Results of the Echo Model. <i>Journal of Hepatology</i> , 2016, 64, S818-S819.	3.7	2
237	Diversity of clinical presentation and virological characteristics of hepatitis delta in different regions world-wide: results of the Hepatitis Delta International network. <i>Journal of Hepatology</i> , 2017, 66, S257-S258.	3.7	2
238	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. <i>Clinics in Liver Disease</i> , 2019, 23, 511-519.	2.1	2
239	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. <i>Clinics in Liver Disease</i> , 2019, 23, 521-534.	2.1	2
240	Point of Care Diagnostic Testing for Hepatitis B Virus. <i>Current Hepatology Reports</i> , 2020, 19, 245-253.	0.9	2
241	Surgical Treatment of Hepatocellular Carcinoma: Resection Versus Transplantation. <i>Difficult Decisions in Surgery: an Evidence-based Approach</i> , 2016, , 73-84.	0.0	2
242	Monotherapy vs multiple-drug therapy: The experts debate. <i>Cleveland Clinic Journal of Medicine</i> , 2009, 76, S20-S24.	1.3	2
243	Hepatocellular Carcinoma: Current Questions and Future Directions. <i>Gastroenterology and Hepatology</i> , 2015, 11, 182-5.	0.1	2
244	Hepatitis D Virus: A Call to Screening. <i>Gastroenterology and Hepatology</i> , 2014, 10, 647-86.	0.1	2
245	HBV/HCV Coinfection and Possible Reactivation of HBV Following DAA Use. <i>Gastroenterology and Hepatology</i> , 2017, 13, 292-295.	0.1	2
246	Letter to the editor: Importance of universal screening for chronic hepatitis B infection in adults in the United States. <i>Hepatology</i> , 2022, 75, 1062-1063.	7.3	2
247	An Evidence-based Practical Guide to Vaccination for Hepatitis B Virus. <i>Journal of Clinical Gastroenterology</i> , 2022, Publish Ahead of Print, .	2.2	2
248	Clinical Application of Induced Hepatocyte-like Cells Produced from Mesenchymal Stromal Cells: A Literature Review. <i>Cells</i> , 2022, 11, 1998.	4.1	2
249	Hepatitis C and hepatocellular carcinoma in African Americans. <i>Gastroenterology</i> , 2000, 118, A1435.	1.3	1
250	Failure to identify specific sequence variations in genotype 1b HCV NS58 associated with response to interferon/ribavirin therapy. <i>Gastroenterology</i> , 2001, 120, A367.	1.3	1
251	Studying the Treatment of Chronic Hepatitis B Viral Infection in Special Populations. , 2004, 96, 465-498.		1
252	Maximizing the benefits of antiviral therapy for HCV: the advantages of treating side effects. <i>Gastroenterology Clinics of North America</i> , 2004, 33, xxiii-xxiv.	2.2	1

#	ARTICLE	IF	CITATIONS
253	Treating HCV with ribavirin analogues and ribavirin-like molecules. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 488-488.	3.0	1
254	Improving clinical trial design for hepatocellular carcinoma treatments. <i>Oncology Reviews</i> , 2007, 1, 45-52.	1.8	1
255	Chronic Hepatitis B Viral Infection. , 0, , 2112-2138.		1
256	LP55 : Response guided therapy is not dead: Low Sustained Virologic Response (SVR) rates in patients who have detectable Hepatitis C Virus (HCV) at week 4 of treatment with SOFOSBUVIR (SOF) containing regimens. <i>Journal of Hepatology</i> , 2015, 62, S290.	3.7	1
257	Low Sustained Virologic Response (SVR) Rates in Genotype (GT) 2 and 3 Patients with Quantifiable Hepatitis C Virus (HCV) at Week 4 of Treatment with Sofosbuvir (SOF) Containing Regimens. <i>Journal of Hepatology</i> , 2016, 64, S786.	3.7	1
258	The Prevalence of Non-Alcoholic Steatohepatitis among Diabetic Patients Followed by Primary Care and Endocrinology. <i>Journal of Hepatology</i> , 2016, 64, S486.	3.7	1
259	Identification of recombinant strains in <sc>HCV</sc> genotype 1 and 3: Is it needed?. <i>Liver International</i> , 2018, 38, 958-958.	3.9	1
260	Significant Hepatic Fibrosis Among Treatment-Naive Chronic Hepatitis B Virus With Increased Hepatitis B Virus DNA and Normal Alanine Aminotransferase. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 146-148.	4.4	1
261	We Are All Africans: A Highly Personal Migratory View of the History of Hepatitis B. <i>Clinical Liver Disease</i> , 2020, 16, 24-33.	2.1	1
262	Autoimmune Hepatitis in Cuban Patients: A Retrospective Analysis of Clinical and Histological Profiles, Treatments, and Outcomes. <i>Current Therapeutic Research</i> , 2020, 93, 100594.	1.2	1
263	Geographic regions with high prevalence of nonalcoholic steatohepatitis-related hepatic fibrosis are also observed to demonstrate high prevalence of metabolic disease risk factors and low consumption of fruits and vegetables. <i>Clinical Nutrition Experimental</i> , 2020, 30, 15-26.	2.0	1
264	Evolving New Strategies for the Medical Management of Chronic Hepatitis B Virus Infection. <i>Gastroenterology and Hepatology</i> , 2016, 12, 679-689.	0.1	1
265	Risk Factors and Treatment for Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2006, 2, 477-478.	0.1	1
266	Medical therapies to extend survival in hepatocellular carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 1-14; quiz 15.	0.3	1
267	Clinical roundtable monograph. Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 2 p preceding 4-15.	0.3	1
268	Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11 Suppl 5, 1-22; quiz 2 p following p22.	0.3	1
269	Editorial: tenofovir alafenamide fumarate“a new silver bullet to prevent mother-to-child transmission of hepatitis B virus. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1744-1745.	3.7	1
270	Variation in Antibody Reactivity to the Hepatitis C Virus by Comparative Immunoscreening and Enzyme Immunoassay. <i>Viral Immunology</i> , 1993, 6, 49-54.	1.3	0

#	ARTICLE	IF	CITATIONS
271	Chemo-embolization for treatment of hepatocellular carcinoma discovered while awaiting liver transplantation: A two-center experience. <i>Gastroenterology</i> , 2000, 118, A1010-A1011.	1.3	0
272	"Delayed" HCV RNA clearance on rebetron therapy: A comparison of week 12 responders VS. late responders. <i>Gastroenterology</i> , 2000, 118, A947.	1.3	0
273	Keratin 8 mutations in patient with cryptogenic liver disease. <i>Gastroenterology</i> , 2001, 120, A45.	1.3	0
274	Potential reduction of post-transplantation HCV-related disease progression by a better selection of the donor. <i>Journal of Hepatology</i> , 2002, 36, 175-176.	3.7	0
275	Epidemiological and clinical differences between hepatitis B virus genotype B with and without recombination with genotype C. <i>Gastroenterology</i> , 2003, 124, A761-A762.	1.3	0
276	Hepatitis B in Liver Transplant Recipients as a Special Model of Antiviral Drug Development. , 2004, 96, 319-342.		0
277	Entecavir. <i>Drugs</i> , 2006, 66, 1623-1624.	10.9	0
278	787 NEGATIVE TISSUE PCR DOES NOT CONFER REDUCED RISK OF RELAPSE AFTER TREATMENT OF HCV IN PATIENTS POST-LIVER TRANSPLANT. <i>Journal of Hepatology</i> , 2008, 48, S294.	3.7	0
279	W1012 Treatment of Hepatitis C Associated Severe Mixed Cryoglobulinemic Syndrome with Plasma Exchange Improves Tolerability and Response to Interferon-Based Therapy. <i>Gastroenterology</i> , 2008, 134, A-832.	1.3	0
280	The new epidemiology of hepatitis B in the United States. <i>Current Hepatitis Reports</i> , 2009, 8, 3-9.	0.3	0
281	W1811 HBV Screening in Asian Pacific Islander Americans: An Interim Analysis of the Hep B Free Program. <i>Gastroenterology</i> , 2009, 136, A-867.	1.3	0
282	W1816 HBV Management Among US Clinicians: Gaps in Clinical Competence and Practice Performance—Survey Findings. <i>Gastroenterology</i> , 2009, 136, A-868.	1.3	0
283	T1002 Clinical Epidemiology of Wilson Disease in Patients with Concurrent Liver Disease. <i>Gastroenterology</i> , 2009, 136, A-844.	1.3	0
284	469 Decline in Hepatitis B Surface Antigen Levels With Entecavir Treatment in HBeAg-Positive Nucleoside Naïve Chronic Hepatitis B Patients-Results From Phase III Study ETV-022. <i>Gastroenterology</i> , 2012, 142, S-917.	1.3	0
285	Su2034 Inhibition of Hec-1 as a Novel Approach to the Treatment of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2012, 142, S-978.	1.3	0
286	HCV In At Risk Populations: Who Can be Treated and How?. <i>Current Hepatitis Reports</i> , 2012, 11, 1-9.	0.3	0
287	516 Impact of Entecavir Versus Lamivudine on Hepatic Covalently Closed-Circular DNA and Total Hepatic HBV DNA in Nucleoside-Naïve HBeAg Positive Chronic Hepatitis B Patients. <i>Gastroenterology</i> , 2013, 144, S-950.	1.3	0
288	Mo1047 HCC Surveillance: An Inquiry Into Current Practices in the United States. <i>Gastroenterology</i> , 2014, 146, S-995.	1.3	0

#	ARTICLE	IF	CITATIONS
289	Spontaneous Regression of HCC: A Case Report. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, e112.	4.4	0
290	Unilateral Sensori-Neural Hearing Loss Induced by Pegylated Interferon $\hat{I}\pm 2a$: A Case Report. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, e113.	4.4	0
291	Sa1854 Birth Cohort-Specific Disparities in Hepatocellular Carcinoma (HCC) Outcomes: Individuals Born Between 1945 to 1965 Have Higher Rates of HCC With Milan Criteria, Higher Rates of HCC Treatment, and Significantly Higher Long-Term Survival. <i>Gastroenterology</i> , 2015, 148, S-1025.	1.3	0
292	953 Race/Ethnicity-Specific Disparities in Cancer Incidence, Burden of Disease, and Overall Survival Among Patients With Hepatocellular Carcinoma in the U.S.: An Updated Analysis of the Surveillance, Epidemiology, and End Results Cancer Registry. <i>Gastroenterology</i> , 2015, 148, S-185.	1.3	0
293	Tu1653 Bringing HCV Treatment to the Community: Preliminary Clinical Outcomes of an FQHC-based HCV Treatment Program. <i>Gastroenterology</i> , 2016, 150, S1157.	1.3	0
294	Chronic Hepatitis B Viral Infection. , 2016, , 387-391.		0
295	High Rates of Surface Antigen Loss and Sustained Viral Suppression in Asian Chronic Hepatitis B Patients Treated with Oral Antiviral Therapy: Community-Based Real World Outcomes. <i>Journal of Hepatology</i> , 2016, 64, S601.	3.7	0
296	424 Development of a Community-Based Testing, Linkage, and Hepatitis C Treatment Program. <i>Gastroenterology</i> , 2016, 150, S1033.	1.3	0
297	Treatment outcomes of hepatitis C virus recombinant form 2k/1b with sofosbuvir based regimens in Georgia. <i>Journal of Hepatology</i> , 2017, 66, S302-S303.	3.7	0
298	Sa1516 - Widening Disparities in Model for End Stage Liver Disease Scores at Time of Liver Transplant Waitlist Registration and at Time of Liver Transplantation: an Analysis of the 2005-2016 United Network for Organ Sharing Registry Data. <i>Gastroenterology</i> , 2018, 154, S-1139-S-1140.	1.3	0
299	Entecavir versus other oral antiviral drugs for chronic hepatitis B. <i>The Cochrane Library</i> , 0, , .	2.8	0
300	Su1472 - African Americans and Patients with Alcoholic Liver Disease have Significantly Higher Model for end Stage Liver Disease (MELD) Scores at Time of Waitlist Registration and at Time of Liver Transplantation. <i>Gastroenterology</i> , 2018, 154, S-531.	1.3	0
301	LBP-38-Increasing Number of Metabolic Co-Morbidities are Associated with Higher Risk of Advanced Fibrosis in Patients with Nonalcoholic Steatohepatitis. <i>Journal of Hepatology</i> , 2019, 70, e160.	3.7	0
302	SAT-494-Global hepatocellular carcinoma mortality trends: An analysis of the world health organization cancer mortality database. <i>Journal of Hepatology</i> , 2019, 70, e851-e852.	3.7	0
303	Tu1185 OLDER AGE AND PRESENCE OF ADVANCED FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE PATIENTS IS ASSOCIATED WITH SIGNIFICANTLY GREATER HEALTHCARE RESOURCE UTILIZATION OF RADIOLOGY SERVICES. <i>Gastroenterology</i> , 2020, 158, S-1010.	1.3	0
304	Mo1459 SEX-SPECIFIC AND RACE/ETHNICITY-SPECIFIC DIFFERENCES IN PERFORMANCE CHARACTERISTICS OF NON-INVASIVE SEROLOGICAL SCORING SYSTEMS TO PREDICT ADVANCED FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE PATIENTS. <i>Gastroenterology</i> , 2020, 158, S-1411.	1.3	0
305	Improving clinical trial design for hepatocellular carcinoma treatments. <i>Oncology Reviews</i> , 2011, 1, .	1.8	0
306	Improving clinical trial design for hepatocellular carcinoma treatments. <i>Oncology Reviews</i> , 2011, 1, 45.	1.8	0

#	ARTICLE	IF	CITATIONS
307	A Case of IgG4-Related Disease: A Unique Presentation of a Rare Entity. American Journal of Gastroenterology, 2015, 110, S109-S110.	0.4	0
308	Recurrent Post-partum Jaundice: Rare Genetic Disorder With Novel Genetic Mutations Identified. American Journal of Gastroenterology, 2015, 110, S397.	0.4	0
309	Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma. Gastroenterology and Hepatology, 2010, 6, 1-16.	0.1	0
310	Delta virus infection: epidemiology and initiatives to intercept it. Gastroenterology and Hepatology, 2013, 9, 589-91.	0.1	0
311	1066. Immune Escape Mutant Detection Using Commercially Available Methods for Hepatitis B Surface Antigen Serological Testing. Open Forum Infectious Diseases, 2020, 7, S562-S562.	0.9	0
312	Current developments in the treatment of hepatitis and hepatobiliary disease. Clinical Advances in Hematology and Oncology, 2006, 4, 511-2.	0.3	0
313	Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol-associated liver disease need our attention. Hepatology, 2022, 76, E7-E8.	7.3	0
314	Title is missing!. , 2019, 14, e0220612.		0
315	Title is missing!. , 2019, 14, e0220612.		0
316	Title is missing!. , 2019, 14, e0220612.		0
317	Title is missing!. , 2019, 14, e0220612.		0
318	Chronic Hepatitis B Viral Infection. , 0, , 636-641.		0